Transforming Medicine with Pharmacogenomics

Exam-Focused Notes on Pharmacogenomics

Definition and Importance:

• Pharmacogenomics: Study of how genes affect a person's response to drugs, transitioning medication prescribing from a trial-and-error method to a precision approach.

Key Genetic Components:

• Cytochrome P450 (CYP) Enzymes: Essential for drug metabolism, with variants affecting drug efficacy and safety.
  • 75% of common medications processed by these enzymes.
  • Genetic variations create distinct metabolizer phenotypes:
    • Poor Metabolizers: Risk of toxic drug accumulation.
    • Ultrarapid Metabolizers: Risk of sub-therapeutic dosing.

Statistics:

• Approximately 90% of the population carries at least one actionable pharmacogenetic variant.

Clinical Applications:

1. Warfarin: Variants in CYP2C9 and VKORC1 genes dictate dosing, with genotype-guided approaches leading to improved outcomes and reduced bleeding risks.
2. Clopidogrel: Metabolism requires CYP2C19; 25-30% of people may face increased cardiovascular event risks due to variant presence.

Psychiatric and Oncological Pharmacogenomics:

• Antidepressants and antipsychotics metabolized by CYP2D6 and CYP2C19 lead to significant variation in effects and side effects.
• Testing for DPYD gene variants before chemotherapy prevents severe toxicity.

Economic Considerations:

• Cost of genetic testing has decreased significantly (from thousands to $200-500).
• Cost-effectiveness frameworks consider:
  • Severity and costs of adverse drug reactions.
  • Frequency of variants in the population.
  • Alternatives available.

Examples of Cost-Effective Testing:

• HLA-B*57:01 testing before Abacavir prescription prevents serious reactions like Stevens-Johnson syndrome.

Barriers to Widespread Adoption:

• Knowledge gaps among healthcare providers due to insufficient training in pharmacogenomics.
• Infrastructure limitations: Many electronic health records lack decision-support tools for integrating pharmacogenomic data.
• Reimbursement uncertainty impacts testing uptake.
• Cultural resistance to changing established prescribing practices.

Future Directions:

• Emphasis on pre-emptive testing strategies to integrate pharmacogenomic data throughout patients' healthcare journeys.
• Potential for whole-genome sequencing to enhance the routine use of pharmacogenomics in preventive medicine.

Constitutional and Legal Context:

• Although specific articles or amendments are not cited, the implementation of pharmacogenomics has implications for patient rights in terms of personalized healthcare.

Conclusion: Pharmacogenomics signifies a paradigm shift toward personalized medicine, enhancing healthcare efficacy through genetic insights. This requires overcoming barriers such as provider education, integrated health systems, and cultural acceptance for effective implementation.